The article discusses the recent launch of the Wegovy oral tablets by Novo Nordisk, which has significantly impacted telemedicine provider LifeMD’s business, with new patient registrations doubling. The Wegovy pill, available since January, has attracted tens of thousands of new users, many new to GLP-1 medications, prompting investors to reassess the oral GLP-1 market.
Eli Lilly’s oral competitor, Foundayo, launched recently but seems to be gaining traction at a slower pace. Analysts noted that Novo’s previous challenges in production could counterbalance Lilly’s manufacturing advantages. Wegovy tablets are marketed for their efficacy, with advertisements featuring celebrities, while emphasizing their affordability compared to injections.
Patients prefer the oral form due to concerns about injections and costs, increasing accessibility in weight loss treatments. While Lilly reports early interest in Foundayo, its marketing efforts have yet to reach the scale of Wegovy’s initial campaign.
Novo is also expanding its manufacturing capacity to meet demand, with plans to introduce Wegovy tablets in Europe. The upcoming earnings report will provide further insights into Wegovy’s performance, as analysts remain cautiously optimistic about both companies’ futures in the competitive GLP-1 market.
Source link
